Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by juniper88on May 14, 2022 11:13pm
151 Views
Post# 34684515

RE:RE:RE:RE:RE:RE:RE:Bigger institutional investors are adding to their position

RE:RE:RE:RE:RE:RE:RE:Bigger institutional investors are adding to their position 1st line for high grade ovarian cancer is Carboplatin with taxol. After a patient becomes platinum resistant, next up is either weekly taxol or doxorubicin, efficacy is equivalent but side effects are different. My wife's first line was 6 cycles of Carboplatin with Taxol. Second line was 5 cycles of Carboplatin with Taxol. Third line 8 cycles of Carboplatin with pegylated doxorubicin. (They allowed the Carboplatin because almost a year had passed since the last cycle of Carboplatin.) This is for high grade ( about 70% of ovarian cancer patients) . There are 3 other types of ovarian cancer. And many subtypes. Also, there now are maintenance treatments like Avastin and parp inhibitors, but they don't count as separate lines ot treatments.
qwerty22 wrote:

"Also, it has been said here that docetaxel is indicated as a first line treatment in ovarian cancer but nothing is said about ovarian on the label for docetaxel (see link below). Anyone want to offer an explanation for that? "
 

It is doxorubicin that's the ovarian cancer drug. So relevant for th1904. I don't think docetaxel has ever been an ovarian cancer drug.
 



<< Previous
Bullboard Posts
Next >>